Reporting from: – European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna – Journal of Clinical Oncology – New England Journal of Medicine – Lancet
Reporting from:
– European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna
– Journal of Clinical Oncology
– New England Journal of Medicine
– Lancet
In this edition:
The ESMO conference in Vienna heard news from Charles Butts that patients with advanced lung cancer have responded to a vaccine.
Diane Harper describes from her article the protection a vaccine has given against human papillomavirus types 16 and 18, raising hopes that widespread prevention of cervical cancer could be undertaken by immunization.
Daniel Haller told delegates at ESMO that his phase III study shows that the IROX combination of irinotecan plus oxaliplatin is superior to irinotecan monotherapy and does not add toxicity.
George Canellos reflects on the immune processes holding follicular lymphoma cells in check as revealed by a New England Journal of Medicine article looking at gene profiles and their prognostic implications for this variable disease.
…
Related Episodes
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer
Aan identifyable subset of patients with high-risk ER+ HER2- early breast cancer better off without chemotherapy